OUR RESOURCES

All of Biotech and Money's content, in one place.

EXECUTIVE AND EXPERT INSIGHTS

Carmell Therapeutics advances plasma-based products with $4m Series B support

Key learnings: Carmell™ Therapeutics closed its Series B round in June 2017...

Read More

Investor perspective: Sander Slootweg

Looking back at the past year, 2017 has proven to be a pretty successful ye...

Read More

Life sciences IPOs: Five things to consider

After spending all day on Wednesday 7 February at Biotech & Money’s IPO wor...

Read More

Desperately seeking alpha: the quest for value

"VC investor seeking long-term relationship. WLTM small cap, early-stage, o...

Read More

Leveraging larger capital pools in Europe

On 5 February 2018, the 4th annual Biotech and Money/Medtech and Money Worl...

Read More

The growth finance landscape in biotech 

The state of the market While the European venture capital market has faced...

Read More

INFOGRAPHIC: 2018 INVESTOR PERCEPTION SURVEY HIGHLIGHTS

This infographic presents key findings from the 2nd Biotech and Money Inves...

Read More

CRISPR in Europe: patent protection and the importance of robust priority claims 

CRISPR, the revolutionary gene-editing technology, presents huge opportunit...

Read More
View More

EXECUTIVE PUBLICATIONS AND REPORTS

INFOGRAPHIC: 2018 INVESTOR PERCEPTION SURVEY HIGHLIGHTS

This infographic presents key findings from the 2nd Biotech and Money Inves...

Read More

Read the Biotech and Money Investor Perception Survey 2018

The Investor Perception Survey 2018 is now available to download. The repor...

Read More

Infographic: 2017 Investor Perception Survey Highlights

In February 2017, Biotech and Money published its 1st Investor perception s...

Read More

A guide to successful investment in advanced therapies

The advanced therapy sector is a rapidly growing industry which offers subs...

Read More

Global therapeutic IPO market: Q3 2017 analysis

The global therapeutic IPO market has failed to maintain the upward momentu...

Read More

How will China’s Cybersecurity Law impact the life sciences sector?

Key learnings: The Cybersecurity Law came into effect in China’s territorie...

Read More

Advice for investors

This blog is a summary of Chapter 6 of the Advanced Therapies Investment Re...

Read More

Understanding Biopharma Interest

This blog is a summary of Chapter 5 of the Advanced Therapies Investment Re...

Read More
View More

INVESTORVIEWS

Investor perspective: Sander Slootweg

Looking back at the past year, 2017 has proven to be a pretty successful ye...

Read More

Investorview: Proactively Bridging The Early Stage Funding Gap

Sinclair Dunlop, Managing Partner at Epidarex Capital Venture capital firm ...

Read More

Investorview: Dr Z Haroon on Julz Co’s recent investments

Julz Co focuses on healthcare investments across the US, Europe, and Asia-P...

Read More

Investorview - Edward Van Wezel, Managing Director, Biogeneration Ventures

We recently sat with Edward Van Wezel, Managing Director and Founder of Bio...

Read More

Investorview - Investing in a Digital Future with Christoph Ruedig, Partner, Albion Capital

Our latest investorview this week is with Christoph Ruedig, Partner at Albi...

Read More

Investorview – Precision Investing with Jay Goth, Managing Partner, Forentis Fund

Our latest investorview is, this week, with Jay Goth, Managing Partner of t...

Read More

Investorview – Zishan Haroon, Chairman & General Partner at ‎Julz Co

In a new regular feature for Drugs & Dealers, we’ll be interviewing some of...

Read More
VIEW MORE